Johnson & Johnson’s Janssen division has launched a global public health group. Janssen said in its Thursday announcement that the new division will unify Janssen’s “commitment to research, develop and deliver transformational medicines to address the world’s greatest unmet public health needs.”
Paul Stoffels, who is chief scientific officer of J&J and worldwide chairman of Janssen, said in a statement that the new unit gives the company “a more focused approach to further develop and introduce our most promising medicines.”
The unit is also charged with increasing medication access and will build on and incorporate practices from Janssen’s global access and partnerships program, which is focused on increasing access to HIV medications.
